Prof. Tom Vanden Berghe and Prof. Koen Augustyns have received a 1.7M euro FWO-SBO grant to pave the way for a ferroptosis spin-off company. Together with a KULeuven team of transplantation surgeons, they will introduce ferroptosis inhibitors into the clinical practice of organ transplantation.
